172 related articles for article (PubMed ID: 23741352)
1. Zoledronic acid sensitizes renal cell carcinoma cells to radiation by downregulating STAT1.
Kijima T; Koga F; Fujii Y; Yoshida S; Tatokoro M; Kihara K
PLoS One; 2013; 8(5):e64615. PubMed ID: 23741352
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of STAT1 sensitizes renal cell carcinoma cells to radiotherapy and chemotherapy.
Zhu H; Wang Z; Xu Q; Zhang Y; Zhai Y; Bai J; Liu M; Hui Z; Xu N
Cancer Biol Ther; 2012 Apr; 13(6):401-7. PubMed ID: 22262126
[TBL] [Abstract][Full Text] [Related]
3. Radiosensitization by inhibiting STAT1 in renal cell carcinoma.
Hui Z; Tretiakova M; Zhang Z; Li Y; Wang X; Zhu JX; Gao Y; Mai W; Furge K; Qian CN; Amato R; Butler EB; Teh BT; Teh BS
Int J Radiat Oncol Biol Phys; 2009 Jan; 73(1):288-95. PubMed ID: 19100922
[TBL] [Abstract][Full Text] [Related]
4. Involvement of the mevalonate pathway in the antiproliferative effect of zoledronate on ACHN renal cell carcinoma cells.
Fujita M; Tohi M; Sawada K; Yamamoto Y; Nakamura T; Yagami T; Yamamori M; Okamura N
Oncol Rep; 2012 May; 27(5):1371-6. PubMed ID: 22322451
[TBL] [Abstract][Full Text] [Related]
5. Loss of interferon-gamma inducibility of TAP1 and LMP2 in a renal cell carcinoma cell line.
Dovhey SE; Ghosh NS; Wright KL
Cancer Res; 2000 Oct; 60(20):5789-96. PubMed ID: 11059775
[TBL] [Abstract][Full Text] [Related]
6. CCN1, a candidate target for zoledronic acid treatment in breast cancer.
Espinoza I; Liu H; Busby R; Lupu R
Mol Cancer Ther; 2011 May; 10(5):732-41. PubMed ID: 21393426
[TBL] [Abstract][Full Text] [Related]
7. Zoledronic acid decreases mRNA six-transmembrane epithelial antigen of prostate protein expression in prostate cancer cells.
Valenti MT; Giannini S; Donatelli L; Realdi G; Lo Cascio V; Dalle Carbonare L
J Endocrinol Invest; 2010 Apr; 33(4):244-9. PubMed ID: 19915386
[TBL] [Abstract][Full Text] [Related]
8. Targeting mTOR and survivin concurrently potentiates radiation therapy in renal cell carcinoma by suppressing DNA damage repair and amplifying mitotic catastrophe.
Rachamala HK; Madamsetty VS; Angom RS; Nakka NM; Dutta SK; Wang E; Mukhopadhyay D; Pal K
J Exp Clin Cancer Res; 2024 Jun; 43(1):159. PubMed ID: 38840237
[TBL] [Abstract][Full Text] [Related]
9. Unbiased analysis of pancreatic cancer radiation resistance reveals cholesterol biosynthesis as a novel target for radiosensitisation.
Souchek JJ; Baine MJ; Lin C; Rachagani S; Gupta S; Kaur S; Lester K; Zheng D; Chen S; Smith L; Lazenby A; Johansson SL; Jain M; Batra SK
Br J Cancer; 2014 Sep; 111(6):1139-49. PubMed ID: 25025965
[TBL] [Abstract][Full Text] [Related]
10. Zoledronic acid induces apoptosis and S-phase arrest in mesothelioma through inhibiting Rab family proteins and topoisomerase II actions.
Okamoto S; Jiang Y; Kawamura K; Shingyoji M; Tada Y; Sekine I; Takiguchi Y; Tatsumi K; Kobayashi H; Shimada H; Hiroshima K; Tagawa M
Cell Death Dis; 2014 Nov; 5(11):e1517. PubMed ID: 25393473
[TBL] [Abstract][Full Text] [Related]
11. Lysosomal-mitochondrial axis in zoledronic acid-induced apoptosis in human follicular lymphoma cells.
Mitrofan LM; Castells FB; Pelkonen J; Mönkkönen J
J Biol Chem; 2010 Jan; 285(3):1967-79. PubMed ID: 19875454
[TBL] [Abstract][Full Text] [Related]
12. Zoledronic acid, a third-generation bisphosphonate, inhibits cellular growth and induces apoptosis in oral carcinoma cell lines.
Tamura T; Shomori K; Nakabayashi M; Fujii N; Ryoke K; Ito H
Oncol Rep; 2011 Apr; 25(4):1139-43. PubMed ID: 21249320
[TBL] [Abstract][Full Text] [Related]
13. Zoledronic acid inhibits proliferation of human fibrosarcoma cells with induction of apoptosis, and shows combined effects with other anticancer agents.
Koto K; Murata H; Kimura S; Horie N; Matsui T; Nishigaki Y; Ryu K; Sakabe T; Itoi M; Ashihara E; Maekawa T; Fushiki S; Kubo T
Oncol Rep; 2010 Jul; 24(1):233-9. PubMed ID: 20514467
[TBL] [Abstract][Full Text] [Related]
14. Zoledronic acid is an effective radiosensitizer in the treatment of osteosarcoma.
Kim EH; Kim MS; Lee KH; Koh JS; Jung WG; Kong CB
Oncotarget; 2016 Oct; 7(43):70869-70880. PubMed ID: 27765919
[TBL] [Abstract][Full Text] [Related]
15. Role of zoledronic acid in oncolytic virotherapy: Promotion of antitumor effect and prevention of bone destruction.
Yamakawa Y; Tazawa H; Hasei J; Osaki S; Omori T; Sugiu K; Komatsubara T; Uotani K; Fujiwara T; Yoshida A; Kunisada T; Urata Y; Kagawa S; Ozaki T; Fujiwara T
Cancer Sci; 2017 Sep; 108(9):1870-1880. PubMed ID: 28685948
[TBL] [Abstract][Full Text] [Related]
16. Effects of bisphosphonate zoledronic acid in hepatocellular carcinoma, depending on mevalonate pathway.
Honda Y; Takahashi S; Zhang Y; Ono A; Murakami E; Shi N; Kawaoka T; Miki D; Tsuge M; Hiraga N; Abe H; Ochi H; Imamura M; Aikata H; Chayama K
J Gastroenterol Hepatol; 2015 Mar; 30(3):619-27. PubMed ID: 25167891
[TBL] [Abstract][Full Text] [Related]
17. Zoledronic acid sensitizes breast cancer cells to fulvestrant via ERK/HIF-1 pathway inhibition in vivo.
Jia X; Cheng J; Shen Z; Shao Z; Liu G
Mol Med Rep; 2018 Apr; 17(4):5470-5476. PubMed ID: 29393454
[TBL] [Abstract][Full Text] [Related]
18. LINC00961 restrains cancer progression via modulating epithelial-mesenchymal transition in renal cell carcinoma.
Chen D; Zhu M; Su H; Chen J; Xu X; Cao C
J Cell Physiol; 2019 May; 234(5):7257-7265. PubMed ID: 30367453
[TBL] [Abstract][Full Text] [Related]
19. Synergistic activity of the histone deacetylase inhibitor suberoylanilide hydroxamic acid and the bisphosphonate zoledronic acid against prostate cancer cells in vitro.
Sonnemann J; Bumbul B; Beck JF
Mol Cancer Ther; 2007 Nov; 6(11):2976-84. PubMed ID: 18025282
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer.
Ottewell PD; Mönkkönen H; Jones M; Lefley DV; Coleman RE; Holen I
J Natl Cancer Inst; 2008 Aug; 100(16):1167-78. PubMed ID: 18695136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
